CK0803

Phase 1Biologic

CCellenkos, Inc.

CK0803 is one of 41 biologic programs targeting Amyotrophic Lateral Sclerosis. It is currently in Phase 1.

Indications

Total Trials

Active Trials

Competitors

Pipeline

Status by Indication[3][1]

Indication

Amyotrophic Lateral SclerosisActive, not recruiting

Amyotrophic Lateral SclerosisPhase 1

Active, not recruiting

Competition

Competitive Landscape

55 competitors in Amyotrophic Lateral Sclerosis

#DrugCompanyPhaseTrials

Nourianz

Kyowa Kirin Co., Ltd.

Vimpat

Enablex

1 4

Bosulif

PPrism Pharmaceuticals

Approved

1 5

Transderm Scop

BBaxter Healthcare Corporation

Avodart

Mirapex

Rocephin

CConrado Roberto Hoffmann Filho

Approved

—9

Rapamune

PPrism Pharmaceuticals

Approved

—10

Precedex

MMcNeil Consumer & Specialty Pharmaceuticals, a Division of McNeil-PPC, Inc.

Approved

—

Ranked by pipeline maturity and clinical activity. Current drug highlighted in teal.

Timeline

Expected Milestones

Q4 2027

Phase 1Active, not recruiting

Amyotrophic Lateral Sclerosis

NCT05695521

Clinical

Trials by Indication[1]

Amyotrophic Lateral Sclerosis1 trial

Phase 1 Safety Run-in Study and Phase 1b Randomized, Double Blinded, Placebo Controlled Trial

Active, not recruiting·CCellenkos, Inc.·Phase 1·NCT05695521·66 enrolled

Sources

References

[1]
ClinicalTrials.gov — 1 trial record for CK0803. U.S. National Library of Medicine, National Institutes of Health.
[2]
ChEMBL — CK0803 compound record. European Bioinformatics Institute (EMBL-EBI).
[3]
Open Targets Platform — Drug–disease associations for CK0803. EMBL-EBI & Wellcome Sanger Institute.
[4]
SEC EDGAR — Cellenkos, Inc. company filings. U.S. Securities and Exchange Commission.

Details

Drug Info

Quick Facts

Modality: Biologic[2]
Highest Phase: Phase 1[1]
Company: CCellenkos, Inc.

CK0803

Status by Indication[3][1]

Competitive Landscape

Expected Milestones

Q4 2027

Trials by Indication[1]

Amyotrophic Lateral Sclerosis1 trial

References

Drug Info

Quick Facts

Related News